<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.3.340">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>chronic-interstitial-lung-diseases-</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
</style>


<script src="chronic-interstitial-lung-diseases-_files/libs/clipboard/clipboard.min.js"></script>
<script src="chronic-interstitial-lung-diseases-_files/libs/quarto-html/quarto.js"></script>
<script src="chronic-interstitial-lung-diseases-_files/libs/quarto-html/popper.min.js"></script>
<script src="chronic-interstitial-lung-diseases-_files/libs/quarto-html/tippy.umd.min.js"></script>
<script src="chronic-interstitial-lung-diseases-_files/libs/quarto-html/anchor.min.js"></script>
<link href="chronic-interstitial-lung-diseases-_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="chronic-interstitial-lung-diseases-_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="chronic-interstitial-lung-diseases-_files/libs/bootstrap/bootstrap.min.js"></script>
<link href="chronic-interstitial-lung-diseases-_files/libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="chronic-interstitial-lung-diseases-_files/libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">


</head>

<body class="fullcontent">

<div id="quarto-content" class="page-columns page-rows-contents page-layout-article">

<main class="content" id="quarto-document-content">



<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B10.jpg" class="img-fluid"></p>
<section id="chronic-interstitial-lung-diseases" class="level1">
<h1>Chronic Interstitial Lung Diseases</h1>
</section>
<section id="serdar-balci-md" class="level1">
<h1>Serdar BALCI, MD</h1>
</section>
<section id="chronic-interstitial-lung-diseases-1" class="level1">
<h1>Chronic Interstitial Lung Diseases</h1>
<p><strong>Chronic Interstitial (Restrictive, Infiltrative) Lung Diseases</strong></p>
<p><strong>Heterogeneous group of disorders</strong></p>
<p><strong>Bilateral, often patchy, usually chronic</strong></p>
<p><strong>Involvement of the pulmonary connective tissue</strong></p>
<p><strong>Most peripheral and delicate interstitium in the alveolar walls</strong></p>
<ul>
<li><strong>Reduced compliance</strong>
<ul>
<li><strong>More pressure is required to expand the lungs</strong></li>
<li><strong>They are stiff</strong></li>
</ul></li>
<li><strong>Increased effort of breathing (dyspnea)</strong></li>
<li><strong>Abnormalities in the ventilation–perfusion ratio → Hypoxia</strong></li>
<li><strong>Respiratory failure, pulmonary hypertension, cor pulmonale</strong></li>
<li><strong>Advanced forms</strong>
<ul>
<li><strong>Scarring and gross destruction of the lung</strong></li>
<li><strong>End-stage or “honeycomb” lung</strong></li>
</ul></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B11.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B12.png" class="img-fluid"></p>
</section>
<section id="fibrosing-diseases" class="level1">
<h1>FIBROSING DISEASES</h1>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B13.png" class="img-fluid"></p>
</section>
<section id="idiopathic-pulmonary-fibrosis" class="level1">
<h1>IDIOPATHIC PULMONARY FIBROSIS</h1>
</section>
<section id="idiopathic-pulmonary-fibrosis-1" class="level1">
<h1>Idiopathic Pulmonary Fibrosis</h1>
<ul>
<li><em>Cryptogenic fibrosing alveolitis</em></li>
<li><strong>Unknown etiology</strong></li>
<li><strong>Patchy, progressive, bilateral interstitial fibrosis</strong></li>
<li><strong>Males are affected more often than females</strong></li>
<li><strong>2/3 of patients &gt;60 years at presentation</strong></li>
<li><em>Usual interstitial pneumonia</em>
<ul>
<li><strong>Radiologic and histologic pattern of fibrosis</strong></li>
</ul></li>
<li><strong>Progressive disease</strong>
<ul>
<li><strong>Die in 3 yrs</strong></li>
<li><strong>Lung transplantation</strong></li>
</ul></li>
<li><strong>Caused by</strong>
<ul>
<li><strong>Repeated cycles of epithelial activation/injury</strong></li>
<li><strong>Some unidentified agent</strong></li>
</ul></li>
<li><strong>Histopathologic features</strong>
<ul>
<li><strong>Inflammation</strong></li>
<li><strong>TH2 response with eosinophils, mast cells, IL-4, and IL-13</strong></li>
<li><strong>Alternatively activated macrophages</strong></li>
<li><strong>Abnormal epithelial repair at the sites of damage and inflammation</strong></li>
<li><strong>Exuberant fibroblastic or myofibroblastic proliferation</strong></li>
<li><strong>Fibroblastic foci</strong></li>
</ul></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B14.png" class="img-fluid"></p>
<p><strong>from injured type I pneumocytes</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B15.png" class="img-fluid"></p>
<ul>
<li><strong>Retraction of scars along the interlobular septa → cobblestones</strong></li>
<li><strong>Fibrosis</strong>
<ul>
<li><strong>Lower lobe predominance</strong></li>
<li><strong>Subpleural regions and along the interlobular septa</strong></li>
</ul></li>
<li><strong>Usual interstitial pneumonia</strong>
<ul>
<li><strong>Patchy interstitial fibrosis</strong></li>
<li><strong>Varies in intensity</strong></li>
</ul></li>
</ul>
<p><strong>Early stages</strong></p>
<p><strong>Alternating areas of light-colored fibrosis and normal lung</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B16.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><strong>the degree of fibrosis increases and small subpleural cysts appear</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B17.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><strong>visceral pleural surface becomes progressively more irregular</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B18.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B19.png" class="img-fluid"></p>
<p><strong>Late stage progressive cyst formation Honeycomb lung</strong></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><strong>Usual interstitial pneumonia. The fibrosis is more pronounced in the subpleural region. </strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B110.png" class="img-fluid"></p>
<p><strong>Usual interstitial pneumonia. Fibrosis in the subpleural region.</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B111.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>Fibroblastic focus with fibers running parallel to surface and bluish myxoid extracellular matrix. Honeycombing is present to the left.</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B112.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<ul>
<li><p><strong>Early lesions</strong></p>
<ul>
<li><strong>Exuberant fibroblastic proliferation</strong></li>
<li><strong>Fibroblastic foci</strong></li>
</ul></li>
<li><p><strong>Over time</strong></p>
<ul>
<li><strong>More collagenous</strong></li>
<li><strong>Less cellular</strong></li>
</ul></li>
<li><p><strong>Existence of both early and late lesions → temporal heterogeneity</strong></p></li>
<li><p><strong>Dense fibrosis → collapse of alveolar walls → formation of cystic spaces</strong></p>
<ul>
<li><strong>Honeycomb fibrosis</strong></li>
</ul></li>
<li><p><strong>Interstitial inflammation</strong></p>
<ul>
<li><strong>Patchy</strong></li>
<li><strong>Lymphocytes and occasional plasma cells, mast cells, and eosinophils</strong></li>
</ul></li>
<li><p><strong>Secondary pulmonary hypertensive changes</strong></p>
<ul>
<li><strong>Intimal fibrosis, medial thickening of pulmonary arteries</strong></li>
</ul></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B113.png" class="img-fluid"></p>
</section>
<section id="nonspecific-interstitial-pneumonia" class="level1">
<h1>NONSPECIFIC INTERSTITIAL PNEUMONIA</h1>
</section>
<section id="nonspecific-interstitial-pneumonia-1" class="level1">
<h1>Nonspecific Interstitial Pneumonia</h1>
<p><strong>Chronic bilateral interstitial lung disease</strong></p>
<p><strong>Unknown etiology</strong></p>
<p><strong>Distinct clinical, radiologic, and histologic features</strong></p>
<p><strong>Much better prognosis than that for IPF</strong></p>
<ul>
<li><strong>Histologic appearance</strong></li>
<li><strong>Cellular pattern</strong>
<ul>
<li><strong>Mild-to-moderate chronic interstitial inflammation</strong></li>
<li><strong>A uniform or patchy distribution</strong></li>
<li><strong>Better outcome than those with the fibrosing pattern and UIP</strong></li>
</ul></li>
<li><strong>Fibrosing pattern</strong>
<ul>
<li><strong>Diffuse or patchy interstitial fibrosis</strong></li>
<li><strong>Without the temporal heterogeneity</strong></li>
</ul></li>
<li><strong>Fibroblastic foci and honeycombing --&gt; in both variants</strong></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B114.png" class="img-fluid"></p>
</section>
<section id="cryptogenic-organizing-pneumonia" class="level1">
<h1>CRYPTOGENIC ORGANIZING PNEUMONIA</h1>
</section>
<section id="cryptogenic-organizing-pneumonia-1" class="level1">
<h1>Cryptogenic Organizing Pneumonia</h1>
<p><strong>Bronchiolitis obliterans organizing pneumonia (BOOP)</strong></p>
<p><strong>Unknown etiology</strong></p>
<p><strong>Cough and dyspnea</strong></p>
<p><strong>Subpleural or peribronchial patchy areas of air space consolidation</strong></p>
<ul>
<li><strong>Histologic examination</strong>
<ul>
<li><strong>Polypoid plugs of loose organizing connective tissue within alveolar ducts, alveoli, and often bronchioles</strong></li>
<li><strong>Connective tissue is all of the same age</strong></li>
<li><strong>Underlying lung architecture is normal</strong></li>
</ul></li>
</ul>
<p><strong>Cryptogenic organizing pneumonia</strong></p>
<p><strong>Alveolar spaces are filled with balls of fibroblasts (Masson bodies)</strong></p>
<p><strong>Adjacent alveoli are relatively normal, compressed</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B115.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B116.png" class="img-fluid"></p>
</section>
<section id="pulmonary-involvement-in-collagen-vascular-diseases" class="level1">
<h1>PULMONARY INVOLVEMENT IN COLLAGEN VASCULAR DISEASES</h1>
</section>
<section id="pulmonary-involvement-in-collagen-vascular-diseases-1" class="level1">
<h1>Pulmonary Involvement inCollagen Vascular Diseases</h1>
<ul>
<li><strong>Systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, dermatomyositis-polymyositis</strong></li>
<li><strong>Several histologic variants can be seen</strong>
<ul>
<li><strong>NSIP, UIP pattern, vascular sclerosis, organizing pneumonia, bronchiolitis</strong></li>
</ul></li>
<li><strong>Pleural involvement</strong>
<ul>
<li><strong>Pleuritis, pleural nodules, and pleural effusion</strong></li>
</ul></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B117.png" class="img-fluid"></p>
</section>
<section id="pneumoconioses" class="level1">
<h1>PNEUMOCONIOSES</h1>
</section>
<section id="pneumoconioses-1" class="level1">
<h1>Pneumoconioses</h1>
<ul>
<li><strong>Non-neoplastic lung reaction to inhalation of mineral dusts</strong>
<ul>
<li><strong>coal dust, silica, asbestos</strong></li>
</ul></li>
<li><strong>Diseases induced by organic as well as inorganic particulates</strong></li>
<li><strong>Chemical fume- and vapor-induced non-neoplastic lung diseases</strong></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B118.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<ul>
<li><strong>Size, shape, solubility, and reactivity of the particles</strong>
<ul>
<li><strong>&gt;5-10 µm are unlikely to reach distal airways</strong></li>
<li><strong>&lt;0.5 µm move into and out of alveoli, often without substantial deposition and injury</strong></li>
<li><strong>1-5 µm in diameter are the most dangerous</strong>
<ul>
<li><strong>Get lodged at the bifurcation of the distal airways</strong></li>
</ul></li>
</ul></li>
<li><strong>Coal dust</strong>
<ul>
<li><strong>Relatively inert</strong></li>
<li><strong>Large amounts required for clinically detectable disease</strong></li>
</ul></li>
<li><strong>Silica, asbestos, and beryllium</strong>
<ul>
<li><strong>More reactive than coal dust</strong></li>
<li><strong>Fibrotic reactions at lower concentrations</strong></li>
</ul></li>
<li><strong>Dust is entrapped in the mucus blanket</strong>
<ul>
<li><strong>Rapidly removed by ciliary movement</strong></li>
</ul></li>
<li><strong>Particles become impacted at alveolar duct bifurcations</strong>
<ul>
<li><strong>Macrophages accumulate and engulf the trapped particulates</strong></li>
<li><strong>Particles activate the inflammasome and induce IL-1 production</strong></li>
</ul></li>
<li><strong>Inflammatory response, fibroblast proliferation, collagen deposition</strong></li>
<li><strong>When particles enter lymphatics → amplification and extension of the local reaction</strong></li>
<li><strong>Tobacco smoking worsens the effects of all inhaled dusts</strong>
<ul>
<li><strong>espescially with asbestos</strong></li>
</ul></li>
</ul>
</section>
<section id="coal-workers-pneumoconiosis" class="level1">
<h1>Coal Worker’s Pneumoconiosis</h1>
<ul>
<li><strong>Pulmonary anthracosis</strong>
<ul>
<li><strong>Most innocuous coal-induced pulmonary lesion in coal miners</strong></li>
<li><strong>Commonly seen in all urban dwellers and tobacco smokers</strong></li>
<li><strong>Carbon pigment engulfed by alveolar or interstitial macrophages</strong></li>
<li><strong>Accumulate in the connective tissue along the lymphatics</strong></li>
<li><strong>Including the pleural lymphatics, in lymph nodes</strong></li>
</ul></li>
<li><strong>Simple CWP</strong>
<ul>
<li><strong>Coal macules</strong></li>
<li><strong>Larger coal nodule</strong></li>
</ul></li>
<li><strong>Coal macule</strong>
<ul>
<li><strong>Dust-laden macrophages</strong></li>
<li><strong>Small amounts of collagen fibers arrayed in a delicate network</strong></li>
<li><strong>Upper lobes and upper zones of the lower lobes</strong></li>
<li><strong>Centrilobular emphysema can occur</strong></li>
</ul></li>
<li><strong>Complicated CWP</strong>
<ul>
<li><strong>Progressive Massive Fibrosis on a background of simple CWP</strong></li>
<li><strong>Coalescence of coal nodules</strong></li>
<li><strong>Years to develop</strong></li>
<li><strong>Multiple, intensely blackened scars</strong></li>
<li><strong>Larger than 2 cm, up to 10 cm</strong></li>
<li><strong>Consist of dense collagen and pigment</strong></li>
</ul></li>
</ul>
<p><strong>Progressive massive fibrosis in a coal worker</strong></p>
<p><strong>Large amount of black pigment is associated with fibrosis</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B119.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>Progressive massive fibrosis superimposed on coal workers’ pneumoconiosis</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B120.png" class="img-fluid"></p>
<ul>
<li><strong>10% of cases of simple CWP progress to PMF</strong></li>
<li><strong>If smoking-related risk has been taken into account</strong>
<ul>
<li><strong>No increased frequency of lung carcinoma in coal miners</strong>
<ul>
<li><strong>Different from silica and asbestos exposures</strong></li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="silicosis" class="level1">
<h1>Silicosis</h1>
<ul>
<li><strong>Most prevalent chronic occupational disease in the world</strong></li>
<li><strong>Inhalation of crystalline silica, in occupational settings</strong></li>
<li><strong>Silica</strong>
<ul>
<li><strong>Crystalline</strong>
<ul>
<li><strong>Quartz, cristobalite, and tridymite</strong>
<ul>
<li><strong>When mixed with other minerals, quartz has a reduced fibrogenic effect</strong>
<ul>
<li><strong>Iron-containing hematite provides a protective effect</strong></li>
</ul></li>
</ul></li>
<li><strong>Most toxic and fibrogenic</strong></li>
</ul></li>
<li><strong>Amorphous forms</strong></li>
</ul></li>
<li><strong>Particles interact with epithelial cells and macrophages</strong></li>
<li><strong>Pulmonary macrophages</strong>
<ul>
<li><strong>IL-1</strong></li>
<li><strong>TNF</strong></li>
<li><strong>Fibronectin</strong></li>
<li><strong>Lipid mediators</strong></li>
<li><strong>Oxygen-derived free radicals</strong></li>
<li><strong>Fibrogenic cytokines</strong></li>
</ul></li>
<li><strong>Anti-TNF monoclonal antibodies can block lung fibrosis in mice</strong></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B121.png" class="img-fluid"></p>
<p><strong>Silicotic nodules</strong></p>
<p><strong>Early stages</strong></p>
<p><strong>Tiny, barely palpable, discrete, pale-to-blackened nodules</strong></p>
<p><strong>Upper zones of the lungs</strong></p>
<p><strong>Advanced silicosis</strong></p>
<p><strong>Scarring contracted the upper lobe into a small dark mass</strong></p>
<p><strong>Dense pleural thickening</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>Concentrically arranged hyalinized collagen fibers</strong></p>
<p><strong>Surrounding an amorphous center</strong></p>
<p><strong>Whorled appearance of the collagen fibers is distinctive for silicosis</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B122.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<ul>
<li><strong>Polarized microscopy</strong>
<ul>
<li><strong>Weakly birefringent silica particles in the center of the nodules</strong></li>
</ul></li>
<li><strong>Disease progresses</strong></li>
<li><strong>Individual nodules may coalesce into hard, collagenous scars</strong></li>
<li><strong>Progression to progressive massive fibrosis</strong></li>
<li><strong>Lung parenchyma may be compressed or overexpanded</strong></li>
<li><strong>Honeycomb pattern may develop</strong></li>
<li><strong>Fibrotic lesions occur in the hilar lymph nodes and pleura</strong></li>
<li><strong>Thin sheets of calcification occur in the lymph nodes</strong>
<ul>
<li><strong>Radiographically as “eggshell” calcification</strong></li>
<li><strong>Calcium surrounding a zone lacking calcification</strong></li>
</ul></li>
<li><strong>End stage lung and heart diseases</strong></li>
<li><strong>Silicosis is associated with an increased susceptibility to tuberculosis</strong>
<ul>
<li><strong>Depression of cell-mediated immunity</strong></li>
<li><strong>Crystalline silica may inhibit the ability of pulmonary macrophages to kill phagocytosed mycobacteria</strong></li>
</ul></li>
<li><strong>Crystalline silica from occupational sources is carcinogenic in humans</strong>
<ul>
<li><strong>The relationship between silica exposure and subsequent lung cancer is controversial</strong></li>
</ul></li>
</ul>
</section>
<section id="asbestosis-and-asbestos-related-diseases" class="level1">
<h1>Asbestosis andAsbestos-Related Diseases</h1>
<p><strong>Occupational exposure to asbestos</strong></p>
<p><strong>Parenchymal interstitial fibrosis (asbestosis )</strong></p>
<p><strong>Localized fibrous plaques or, rarely, diffuse fibrosis in the pleura</strong></p>
<p><strong>Pleural effusions</strong></p>
<p><strong>Lung carcinomas</strong></p>
<p><strong>Malignant pleural and peritoneal mesotheliomas</strong></p>
<p><strong>Laryngeal carcinoma</strong></p>
<p><strong>an asbestos body, revealing the typical beading and knobbed ends </strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B123.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>an asbestos body, revealing the typical beading and knobbed ends </strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B124.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="asbestos" class="level1">
<h1>Asbestos</h1>
<p><strong>Concentration, size, shape, and solubility of the different forms of asbestos affect pathogenesis</strong></p>
<p><strong>Two distinct forms of asbestos</strong></p>
<p><strong>Serpentine</strong></p>
<p><strong>Amphibole</strong></p>
<p><strong>Both are pathogenic for all diseases</strong></p>
</section>
<section id="serpentine" class="level1">
<h1>Serpentine</h1>
<p><strong>Fiber is curly and flexible</strong></p>
<p><strong>Serpentine chrysotile accounts for most of the asbestos used in industry</strong></p>
<p><strong>Impacted in the upper respiratory passages and removed by the mucociliary elevator</strong></p>
<p><strong>Those that are trapped in the lungs are gradually leached from the tissues, because they are more soluble than amphiboles </strong></p>
</section>
<section id="amphibole" class="level1">
<h1>Amphibole</h1>
<p><strong>Fiber is straight, stiff, and brittle</strong></p>
<p><strong>More pathogenic than the serpentine chrysotile</strong></p>
<p><strong>Align themselves in the airstream → delivered deeper into the lungs → penetrate epithelial cells to reach the interstitium</strong></p>
</section>
<section id="both-forms-cause-disease" class="level1">
<h1>Both forms cause disease</h1>
<ul>
<li><strong>Increasing exposure to either form</strong>
<ul>
<li><strong>associated with a higher incidence of all asbestos-related diseases</strong></li>
</ul></li>
<li><strong>Interaction of particulates with lung macrophages → fibrosis</strong></li>
<li><strong>Functions as both a tumor initiator and a promoter</strong>
<ul>
<li><strong>Reactive free radicals generated by asbestos fibers → mesothelial tumors</strong></li>
<li><strong>Potentially toxic chemicals adsorbed onto the asbestos fibers</strong>
<ul>
<li><strong>Tobacco smoking</strong></li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="asbestosis" class="level1">
<h1>Asbestosis</h1>
<p><strong>Diffuse pulmonary interstitial fibrosis</strong></p>
<p><strong>Indistinguishable from UIP</strong></p>
<p><strong>Except for the presence of asbestos bodies</strong></p>
</section>
<section id="asbestos-bodies" class="level1">
<h1>Asbestos Bodies</h1>
<ul>
<li><strong>Golden brown, fusiform or beaded rods with a translucent center</strong></li>
<li><strong>Coated with an iron-containing proteinaceous material</strong></li>
<li><strong>Formed when macrophages attempt to phagocytose asbestos fibers</strong>
<ul>
<li><strong>The iron is derived from phagocyte ferritin</strong></li>
</ul></li>
<li><strong>Can be found in the lungs of normal persons</strong>
<ul>
<li><strong>Much lower concentrations and without an accompanying interstitial fibrosis.</strong></li>
</ul></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B125.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="asbestosis-1" class="level1">
<h1>Asbestosis</h1>
<ul>
<li><strong>Begins in the lower lobes and subpleurally</strong>
<ul>
<li><strong>In contrast with CWP and silicosis</strong></li>
</ul></li>
<li><strong>Middle and upper lobes of the lungs become affected as fibrosis progresses</strong></li>
<li><strong>Contraction of the fibrous tissue</strong>
<ul>
<li><strong>Distorts the normal architecture</strong></li>
<li><strong>Creating enlarged air spaces enclosed within thick fibrous walls</strong></li>
<li><strong>Affected regions become honeycombed</strong></li>
</ul></li>
<li><strong>Fibrosis develops in the visceral pleura</strong>
<ul>
<li><strong>Adhesions between the lungs and the chest wall</strong></li>
</ul></li>
<li><strong>Scarring trap and narrow pulmonary arteries and arterioles</strong>
<ul>
<li><strong>Pulmonary hypertension and cor pulmonale</strong></li>
</ul></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B126.png" class="img-fluid"></p>
<p><strong>Asbestosis</strong></p>
<p><strong>Markedly thickened visceral pleura covers the lateral and diaphragmatic surface</strong></p>
<p><strong>Severe interstitial fibrosis diffusely affecting the lower lobe</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B127.png" class="img-fluid"></p>
</section>
<section id="pleural-plaques" class="level1">
<h1>Pleural plaques</h1>
<p><strong>Most common manifestation of asbestos exposure</strong></p>
<p><strong>Well-circumscribed plaques of dense collagen</strong></p>
<p><strong>Often contain calcium</strong></p>
<p><strong>Most frequently on the anterior and posterolateral aspects of the parietal pleura and over the domes of the diaphragm</strong></p>
<p><strong>Do not contain asbestos bodies</strong></p>
<p><strong>Rarely occur in persons with no history or evidence of asbestos exposure </strong></p>
<p><strong>Uncommonly, asbestos exposure induces pleural effusion or diffuse pleural fibrosis.</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B128.png" class="img-fluid"></p>
</section>
<section id="asbestosis-2" class="level1">
<h1>Asbestosis</h1>
<p><strong>End stage lung and heart diseases</strong></p>
<p><strong>The risk of lung carcinoma is increased 5x</strong></p>
<p><strong>Mesothelioma risk 1000x</strong></p>
<p><strong>Concomitant cigarette smoking greatly increases the risk of lung carcinoma but not that of mesothelioma</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B129.png" class="img-fluid"></p>
</section>
<section id="drug--and-radiation-induced-pulmonary-diseases" class="level1">
<h1>DRUG- AND RADIATION-INDUCED PULMONARY DISEASES</h1>
</section>
<section id="bleomycin" class="level1">
<h1>Bleomycin</h1>
<p><strong>Anticancer agent</strong></p>
<p><strong>Pneumonitis and interstitial fibrosis</strong></p>
<p><strong>Direct toxicity of the drug</strong></p>
<p><strong>Stimulating the influx of inflammatory cells into the alveoli</strong></p>
</section>
<section id="amiodarone" class="level1">
<h1>Amiodarone</h1>
<p><strong>An antiarrhythmic agent</strong></p>
<p><strong>Associated with risk for pneumonitis and fibrosis</strong></p>
</section>
<section id="radiation-pneumonitis" class="level1">
<h1>Radiation pneumonitis</h1>
<ul>
<li><strong>Complication of therapeutic irradiation of pulmonary and other thoracic tumors</strong></li>
<li><strong>Acute radiation pneumonitis</strong>
<ul>
<li><strong>1-6 months after therapy</strong></li>
<li><strong>in as many as 20% of the patients</strong></li>
<li><strong>Fever, dyspnea out of proportion to the volume of irradiated lung, pleural effusion, and development of pulmonary infiltrates corresponding to the area of radiation</strong></li>
<li><strong>May resolve with corticosteroid therapy or progress</strong></li>
</ul></li>
<li><strong>Chronic radiation pneumonitis</strong>
<ul>
<li><strong>Progress from acute form</strong></li>
<li><strong>Associated with pulmonary fibrosis</strong></li>
</ul></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B130.png" class="img-fluid"></p>
</section>
<section id="granulomatous-diseases" class="level1">
<h1>GRANULOMATOUS DISEASES</h1>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B131.png" class="img-fluid"></p>
</section>
<section id="sarcoidosis" class="level1">
<h1>SARCOIDOSIS</h1>
</section>
<section id="sarcoidosis-1" class="level1">
<h1>Sarcoidosis</h1>
<ul>
<li><p><strong>A multisystem disease</strong></p></li>
<li><p><strong>Unknown etiology</strong></p></li>
<li><p><strong>Characterized by noncaseating granulomas in many tissues and organs</strong></p></li>
<li><p><strong>Other diseases sometimes also produce noncaseating granulomas</strong></p>
<ul>
<li><strong>mycobacterial or fungal infections and berylliosis</strong></li>
</ul></li>
<li><p><strong>Diagnosis of sarcoidosis is one of exclusion</strong></p></li>
<li><p><strong>Bilateral hilar lymphadenopathy</strong></p></li>
<li><p><strong>Lung involvement</strong></p>
<ul>
<li><strong>Visible on chest radiographs</strong></li>
</ul></li>
<li><p><strong>Eye and skin involvement, 25% of cases</strong></p></li>
<li><p><strong>Adults &lt;40 year</strong></p></li>
<li><p><strong>Danish and Swedish populations, African Americans (10x whites)</strong></p></li>
<li><p><strong>Higher prevalence among nonsmokers</strong></p></li>
<li><p><strong>Development of a cell-mediated response to an unidentified antigen</strong></p></li>
<li><p><strong>Intra-alveolar and interstitial accumulation of CD4+ T</strong> <strong>H</strong> <strong>1 cells</strong></p></li>
<li><p><strong>Oligoclonal expansion of T cell subsets</strong></p></li>
<li><p><strong>Increases in T cell–derived T</strong> <strong>H</strong> <strong>1 cytokines</strong></p>
<ul>
<li><strong>IL-2 and IFN-γ</strong></li>
</ul></li>
<li><p><strong>T cell expansion and macrophage activation</strong></p></li>
<li><p><strong>Increases in several cytokines in the local environment</strong></p>
<ul>
<li><strong>IL-8, TNF, macrophage inflammatory protein-1α</strong></li>
</ul></li>
<li><p><strong>Recruitment of additional T cells and monocytes</strong></p></li>
<li><p><strong>Formation of granulomas</strong></p></li>
<li><p><strong>Anergy to common skin test antigens</strong></p>
<ul>
<li><strong>Candida or purified protein derivative (PPD)</strong></li>
<li><strong>Result from pulmonary recruitment of CD4+ T cells</strong></li>
<li><strong>Peripheral depletion</strong></li>
</ul></li>
<li><p><strong>Polyclonal hypergammaglobulinemia</strong></p></li>
<li><p><strong>Association with HLA-A1 and HLA-B8</strong></p></li>
<li><p><strong>After lung transplantation, sarcoidosis recurs in the new lungs in 75%</strong></p></li>
<li><p><strong>Putative antigens have been proposed</strong></p>
<ul>
<li><strong>Viruses, mycobacteria, Borrelia, pollen</strong></li>
<li><strong>No proof</strong></li>
</ul></li>
</ul>
</section>
<section id="histopathologic-feature-of-sarcoidosis" class="level1">
<h1>Histopathologic feature of sarcoidosis</h1>
<ul>
<li><strong>Noncaseating epithelioid granuloma, irrespective of the organ involved</strong></li>
<li><strong>Discrete, compact collection of epithelioid cells</strong></li>
<li><strong>Rimmed by an outer zone of largely CD4+ T cells</strong></li>
<li><strong>Epithelioid cells are derived from macrophages and are characterized by abundant eosinophilic cytoplasm and vesicular nuclei</strong></li>
<li><strong>Intermixed multinucleate giant cells formed by fusion of macrophages</strong></li>
<li><strong>A thin layer of laminated fibroblasts is present peripheral to the granuloma</strong></li>
<li><strong>Over time</strong>
<ul>
<li><strong>Entire granuloma with a hyalinized scar</strong></li>
</ul></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B132.png" class="img-fluid"></p>
<p><strong>Sarcoid</strong></p>
<p><strong>Characteristic peribronchial noncaseating granulomas with many giant cells</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<ul>
<li><strong>Schaumann bodies</strong>
<ul>
<li><strong>Laminated concretions composed of calcium and proteins</strong></li>
</ul></li>
<li><strong>Asteroid bodies</strong>
<ul>
<li><strong>Stellate inclusions enclosed within giant cells</strong></li>
</ul></li>
<li><strong>They are not specific</strong></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B133.jpg" class="img-fluid"></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B134.jpg" class="img-fluid"></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B135.jpg" class="img-fluid"></p>
</section>
<section id="sarcoidosis-2" class="level1">
<h1>Sarcoidosis</h1>
<ul>
<li><strong>Skin</strong>
<ul>
<li><strong>Erythema nodosum</strong></li>
</ul></li>
<li><strong>Eye</strong>
<ul>
<li><strong>Iritis or iridocyclitis</strong></li>
<li><strong>Corneal opacities, glaucoma, total loss of vision</strong></li>
<li><strong>Choroiditis, retinitis, and optic nerve involvement</strong></li>
</ul></li>
<li><strong>Lacrimal glands</strong>
<ul>
<li><strong>Sicca syndrome</strong></li>
</ul></li>
<li><strong>Parotitis</strong>
<ul>
<li><strong>Mikulicz syndrome</strong></li>
</ul></li>
<li><strong>Liver</strong></li>
<li><strong>Spleen</strong></li>
<li><strong>Bone marrow </strong></li>
<li><strong>Hypercalcemia and hypercalciuria</strong>
<ul>
<li><strong>production of active vitamin D by the mononuclear phagocytes in the granulomas</strong></li>
</ul></li>
</ul>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B136.png" class="img-fluid"></p>
</section>
<section id="hypersensitivity-pneumonitis" class="level1">
<h1>HYPERSENSITIVITY PNEUMONITIS</h1>
</section>
<section id="hypersensitivity-pneumonitis-1" class="level1">
<h1>Hypersensitivity Pneumonitis</h1>
<p><strong>Allergic alveolitis</strong></p>
<p><strong>Occupational disease</strong></p>
<p><strong>Heightened sensitivity to inhaled antigens such as in moldy hay</strong></p>
<p><strong>The damage at the level of alveoli</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B137.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<ul>
<li><strong>Bronchoalveolar lavage specimens</strong>
<ul>
<li><strong>increased numbers of T lymphocytes of both CD4+ and CD8+ phenotype.</strong></li>
</ul></li>
<li><strong>Type III hypersensitivity</strong>
<ul>
<li><strong>Specific precipitating antibodies in serum,</strong></li>
<li><strong>Complement and immunoglobulins within vessel walls by immunofluorescence</strong></li>
</ul></li>
<li><strong>Type IV hypersensitivity</strong>
<ul>
<li><strong>Presence of noncaseating granulomas in 2/3 of patients</strong></li>
</ul></li>
<li><strong>Patchy mononuclear cell infiltrates in the pulmonary interstitium</strong></li>
<li><strong>Characteristic peribronchiolar accentuation</strong></li>
<li><strong>Lymphocytes predominate</strong></li>
<li><strong>Plasma cells and epithelioid cells also are present</strong></li>
<li><strong>Acute forms of the disease, neutrophils may be seen</strong></li>
<li><strong>Interstitial noncaseating granulomas</strong>
<ul>
<li><strong>peribronchiolar location</strong></li>
</ul></li>
<li><strong>Advanced chronic cases</strong>
<ul>
<li><strong>Diffuse interstitial fibrosis occurs.</strong></li>
</ul></li>
</ul>
<p><strong>Hypersensitivity pneumonitis</strong></p>
<p><strong>Loosely formed interstitial granulomas and chronic inflammation are characteristic</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B138.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B139.png" class="img-fluid"></p>
</section>
<section id="pulmonary-eosinophilia" class="level1">
<h1>PULMONARY EOSINOPHILIA</h1>
</section>
<section id="pulmonary-eosinphilia" class="level1">
<h1>Pulmonary Eosinphilia</h1>
<p><strong>Infiltration and activation of eosinophils</strong></p>
<p><strong>Elevated levels of alveolar IL-5</strong></p>
<p><strong>Diverse diseases of immunologic origin</strong></p>
</section>
<section id="acute-eosinophilic-pneumonia-with-respiratory-failure" class="level1">
<h1>Acute eosinophilic pneumonia with respiratory failure</h1>
<p><strong>Rapid onset of fever, dyspnea, hypoxia</strong></p>
<p><strong>Diffuse pulmonary infiltrates on chest radiographs</strong></p>
<p><strong>Bronchoalveolar lavage fluid typically contains more than 25% eosinophils Prompt response to corticosteroids</strong></p>
</section>
<section id="simple-pulmonary-eosinophilia" class="level1">
<h1>Simple pulmonary eosinophilia</h1>
<p><strong>Loeffler syndrome</strong></p>
<p><strong>Transient pulmonary lesions</strong></p>
<p><strong>Eosinophilia in the blood</strong></p>
<p><strong>Alveolar septa are thickened by an infiltrate containing eosinophils and occasional giant cells</strong></p>
<ul>
<li><strong>Tropical eosinophilia</strong>
<ul>
<li><strong>Infection with microfilariae and helminthic parasites</strong></li>
</ul></li>
<li><strong>Secondary eosinophilia</strong>
<ul>
<li><strong>Association with asthma</strong></li>
<li><strong>Drug allergies</strong></li>
<li><strong>Vasculitis</strong></li>
</ul></li>
</ul>
</section>
<section id="idiopathic-chronic-eosinophilic-pneumonia" class="level1">
<h1>Idiopathic chronic eosinophilic pneumonia</h1>
<p><strong>Aggregates of lymphocytes and eosinophils within the septal walls and the alveolar spaces</strong></p>
<p><strong>Periphery of the lung fields</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B140.png" class="img-fluid"></p>
</section>
<section id="smoking-related-interstitial-diseases" class="level1">
<h1>SMOKING-RELATED INTERSTITIAL DISEASES</h1>
</section>
<section id="smoking-related-interstitial-diseases-1" class="level1">
<h1>Smoking-Related Interstitial Diseases</h1>
<ul>
<li><strong>Obstructive pulmonary disease</strong>
<ul>
<li><strong>Emphysema</strong></li>
<li><strong>Chronic bronchitis</strong></li>
</ul></li>
<li><strong>Restrictive or interstitial lung diseases</strong>
<ul>
<li><strong>Desquamative interstitial pneumonia (DIP)</strong></li>
<li><strong>Respiratory bronchiolitis</strong></li>
</ul></li>
</ul>
</section>
<section id="desquamative-interstitial-pneumonia" class="level1">
<h1>Desquamative interstitial pneumonia</h1>
<p><strong>Accumulation of large numbers of macrophages</strong></p>
<p><strong>Abundant cytoplasm containing dusty-brown pigment</strong></p>
<p><strong>Smoker’s macrophages</strong></p>
<p><strong>Desquamative interstitial pneumonia</strong></p>
<p><strong>Accumulation of large numbers of macrophages within the alveolar spaces, </strong></p>
<p><strong>Slight fibrous thickening of the alveolar walls</strong></p>
<p><img src="img%5CChronic-Interstitial-Lung-Diseasespptx-kopyas%C4%B141.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<ul>
<li><strong>Alveolar septa are thickened</strong>
<ul>
<li><strong>Sparse inflammatory infiltrate</strong>
<ul>
<li><strong>Lymphocytes</strong></li>
</ul></li>
<li><strong>Interstitial fibrosis</strong>
<ul>
<li><strong>Mild</strong></li>
</ul></li>
</ul></li>
<li><strong>Good prognosis with excellent response to steroid therapy and smoking cessation</strong></li>
</ul>
</section>
<section id="respiratory-bronchiolitis" class="level1">
<h1>Respiratory bronchiolitis</h1>
<p><strong>Pigmented intraluminal macrophages similar to DIP</strong></p>
<p><strong>Bronchiolocentric distribution</strong></p>
<p><strong>Mild peribronchiolar fibrosis</strong></p>
</section>

</main>
<!-- /main column -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    text: function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>